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httpicense.Abstract Aim of the work: The aim of this study was to determine the frequencies and predictors
of maternal and fetal pregnancy outcomes in women with systemic lupus erythematosus (SLE).
Patients and methods: Data of 37 pregnancies of 34 patients with systemic lupus erythematosus
were collected prospectively from patients at Rheumatology and Rehabilitation department of
Cairo University Hospitals from 2007 to 2009. Univariate analysis and logistic regression analysis
were used.
Results: There were ﬁve spontaneous miscarriages, and 32 pregnancies resulting in live births.
There were 20 full term babies and 12 preterm babies. Eight fetuses were born with intrauterine
growth retardation (IUGR) and seven babies were born with low birth weight (LBW). Six babies
were incubated at NICU (premature) with four neonatal deaths. Among 37 pregnancies, 32 women
(86.5%) were in clinical remission before pregnancy; only ﬁve patients (13.5%) were active. There
were 21/32 episodes of SLE ﬂare up (65.6%) during pregnancy and eight postpartum ﬂare up
(21.6%). Eight women (21.6%) developed preeclampsia during pregnancy. Planned pregnancy
and SLEDAI at the beginning of pregnancy were signiﬁcantly associated with fetal loss at univar-
iate analysis. However, there were no signiﬁcant predictors of fetal loss at binary logistic regression
analysis. There was no maternal mortality reported. Renal lupus disease was found to be a predictor
of pre-eclampsia occurrence in univariate analysis (P= 0.04).rtment of Rheumatology and
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134 A. Mokbel et al.Conclusion: In general, pregnancies can be successful in most women with SLE with a favorable
fetal outcome. SLE tends to ﬂare during pregnancy. Flares are maximal during the second trimester.
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Systemic lupus erythematosus (SLE) is a connective tissue
systemic autoimmune disorder that affects women during
their reproductive age years. Although, pregnancy is increas-
ingly common in women with SLE as survival and quality
of life improve [1,2], pregnancy in SLE women is still a high
risk condition with increased maternal and fetal morbidity
and mortality. Increase in SLE disease activity is expected
during pregnancy because of the increasing levels of estro-
gen, progesterone, prolactin and T-helper cells. Thus, close
collaboration of a maternal-fetal medicine specialist and a
rheumatologist in a high risk clinic is essential to success-
fully manage those pregnant women with SLE [3]. The im-
pact of pregnancy on lupus disease has been investigated
but remains controversial, especially with regard to the inci-
dence of disease exacerbations during gestation. In contrast,
the impact of SLE on pregnancy is more clearly understood.
Whatever, women with lupus disease are not less fertile than
unaffected women [4], fetal outcome in lupus pregnancy is
characterized by higher rates of fetal loss, preterm delivery
and intrauterine growth retardation (IUGR) [5] and the
development of neonatal lupus [6]. Thus, the aim of this
study was to assess maternal and fetal outcomes of preg-
nancy in women with SLE and to determine their predictors.
2. Patients and methods
Thirty-seven pregnancies in 34 SLE female patients were en-
rolled in the study. Follow up of the patients was conducted
at Rheumatology and Rehabilitation department of Cairo
University Hospitals from the beginning of 2007–2009. All
patients fulﬁlled the 1997 American College of Rheumatol-
ogy criteria for SLE [7]. Antiphospholipid syndrome (APS)
was diagnosed according to the recent criteria [8]. All pa-
tients were attended by an interdisciplinary team, including
a rheumatologist and a fetal-maternal medicine specialist.
Other specialties were considered if needed. Patients were
seen by the rheumatologist at least once a month from the
diagnosis of pregnancy and at least bi-monthly from the sev-
enth month. Follow up during postpartum period continued
for 6 weeks. At each assessment, a standardized medical his-
tory, physical examination and laboratory evaluation were
performed. Laboratory tests included complete blood count,
erythrocyte sedimentation rate, serum albumin, creatinine le-
vel, liver function tests, urine analysis and 24-h urine collec-
tion for the measurement of protein excretion. Overall
disease activity of SLE was evaluated using the SLE Disease
Activity Index (SLEDAI) [9].
The received prednisone dose usually did not exceed 20 mg/
day in general. Occasionally, disease manifestations necessi-
tated transiently higher dose modiﬁcation. Flares were treated
according to physician’s best judgment. All cases with anti-
phospholipid syndrome (APS) received aspirin 80 mg/day.
Anticoagulation with low molecular weight heparin was givento those with recurrent miscarriage at ﬁrst trimester, one or
more fetal losses at second trimester or history of thrombotic
events. Antenatal assessment included follow up as soon as
pregnancy is conﬁrmed by doing early ultrasound to check fe-
tal viability, then every two weeks till 28 weeks gestation then
weekly till end of pregnancy. Fetal anomaly scan at 20–
22 weeks was performed. In women with anti SSA (Ro) and/
or anti SSB (La), closer fetal heart monitoring was carried
out. The deﬁnitions in Table 1 were used for this study and ap-
plied uniformly to all patients. The glomerulonephritis was
categorized according to the WHO revised classiﬁcation [10].
Statistical analysis: Data were summarized using mean and
standard deviation for quantitative variables and percent for
qualitative variables. In all cases p value <0.05 was considered
to be statistically signiﬁcant. Univariate analysis using Chi-
square test was used to evaluate the impact of clinical and lab-
oratory characteristics on the maternal and fetal outcomes.
Logistic binary regression was used to assess the predictive va-
lue of each variable on binary outcomes taking into account
the interaction or confounding effect of the other covariates.
Each pregnancy was considered as a separate observation.
Analysis was performed using the SPSS 19.0.
3. Results
3.1. Patient characteristics and demographic data
Thirty-seven pregnancies of the 34 patients were analyzed.
The mean age at pregnancy was 26.8 ± 4.5 years old and
the mean interval between diagnosis of SLE and pregnancy
was 6.5 ± 5.4 years. There were 28 (75.7%) multiparous and
nine (24.3%) primiparous women. Fifteen women (40.5%)
had a previous history of early miscarriage. The pregnancy
was planned within 26 (70.3%) of women enrolled in the
study. Sixteen (43.2%) pregnancies were accompanied with
Lupus nephritis Table 2. The percentage of pregnancies with
maternal neuropsychiatric disorders (27%), cutaneous
(89.2%), arthritis (92%), serositis (81.1%) and hematological
(32.4%) affection are shown in Table 2. Twenty patients
(54.1%) were diagnosed as having secondary antiphospho-
lipid syndrome. Hypertension was present in 35% of pa-
tients Table 2. One patient was diabetic. The majority (36
pregnancies, 97.3%) was treated with oral steroid during
pregnancy with dose ranging from 5 to 20 mg/day; low-dose
aspirin was given during 33 (89.2%). All of them received
hydroxychloroquine. Azathioprine was given during 25
(67.6%) pregnancies with dose ranged from 50 to 150 mg/
day and LMWH during 17 (45.9%) pregnancies with no
maternal or fetal adverse effects.
3.2. Fetal outcome and pregnancy complications
Pregnancy outcomes are detailed in Table 3. Thirty-two
(86.5%) pregnancies resulted in live births. The early ﬁrst tri-
Table 1 Outcome deﬁnitions.
Active SLE According to the SLE disease activity index (SLEDAI)
SLE ﬂare Change of the SLEDAI item score and total SLEDAI score
Classiﬁcation of lupus
nephritis and its grades
According to the revised WHO classiﬁcation for lupus nephritis
[10]
Planned pregnancy Medical agreement for the pregnancy that was given when lupus
disease was clinically stable for at least 6 months
Spontaneous miscarriage
rate
Fetal loss before 20 weeks of gestation
Fetal loss Due to spontaneous miscarriage and neonatal death
Intrauterine growth
retardation (IUGR)
Fetus whose weight is below the 10th percentile for the
gestational age
Low birth weight (LBW) Birth weight less than 10th percentile
Preterm birth A live birth before 37th week
Neonatal death Live infant dying within 28 days after delivery
Preeclampsia New onset hypertension and proteinuria after 20 weeks’ gestation
Table 2 Demographic, clinical and laboratory characteristics of the pregnant SLE patients.
Number of pregnancies/number of patients 37/34
Age at the onset of SLE (Mean ± SD) (range) 20.3 ± 5.2 (12–31)
Age at pregnancy (Mean ± SD) (range) 26.8 ± 4.5 (20–38)
Disease duration (Mean ± SD) (range) 6.5 ± 5.4 (1–19)
Multiparous women (n; %) 28/37 (75.7)
Primiparous women (n; %) 9/37 (24.3)
History of miscarriage (n; %) 15/37 (40.5)
Planned pregnancy (n; %) 26/37 (70.3)
Remission phase (n; %) 32/37 (86.5)
Active phase (n; %) 5/37 (13.5)
Articular (n; %) 34/ 37 (91.9)
Cutaneous (n; %) 33/ 37 (89.2)
Serositis (n; %) 30/37 (81.1)
Nephritis (n; %) 16/37 (43.2)
Hypertension (n; %) 13/37 (35)
Neurological manifestations (n; %) 10/37 (27)
Hematological (n; %) 12/37 (32.4)
Secondary antiphospholipid syndrome (APS) 20/37 (54.1)
ACL (IgM) 15/37 (40.5)
ACL (IgG) 18/37 (48.6)
LAC 9/37 (24.3)
Anti-SSA/Ro antibodies 9/37 (24.3)
Anti SSB/La antibodies 9/37 (24.3)
ANA 37/37 (100)
dsDNA 22/37 (59.5)
n: number, SD: standard deviation, ACL: anticardiolipin antibodies, LAC: lupus anticoagulant,
ANA: antinuclear antibody, dsDNA: double stranded DNA.
Could women with systemic lupus erythematosus (SLE) have successful pregnancy 135mester miscarriage rate was 13.5% (n= 5) and preterm birth
rate was 32.4% (n= 12). Full term birth rate was 54.1%
(n= 20). Eight (21.6%) fetuses suffered from intrauterine
growth retardation (IUGR). Seven (18.9%) babies were born
with fetal weight less than normal (LBW); and six babies
(20%) from those that were born live (32) were incubated at
NICU either due to prematurity, respiratory distress syndrome
or LBW/IUGR. Four (10.8%) neonatal deaths were due to
respiratory problem (n= 3) and intracranial hemorrhage
(n= 1). During an echocardiographic follow up of a mother
with positive anti-Ro and anti-La antibodies, intrauterine bra-
dycardia was discovered at 36th week (diagnosed as 1st degree
heart block). Dexamethasone therapy of 4 mg daily was given
to the mother for ten days with improvement of heart rate. The
baby was normal at delivery.3.3. Maternal outcomes
Among 37 pregnancies, 32 women (86.5%) were in clinical
remission before pregnancy; only 5 patients (13.5%) were ac-
tive as determined by SLEDAI index. After exclusion of the
5 patients who were active at the beginning, there were 21/32
episodes of SLE ﬂare up (56.5%). Eight cases of postpartum
ﬂare (21.6%) were recorded. The majority of ﬂare episodes
was in the form of lupus nephropathy and occurred in the sec-
ond trimester of pregnancy Table 4. There were eight women
(21.6%) who developed preeclampsia during pregnancy. There
was no maternal mortality reported. The most common mode
of delivery for the live birth children (86%) was vaginal deliv-
eries (50%). Cesarean section was reported in (36%). The main
Table 3 Overall pregnancy outcomes in the SLE patients.
Miscarriage rate 5/37 (13.5%)
Live birth rate (LBR) 32/37 (81%)
Full term delivery 20/37 (48.6%)
Premature rupture of membrane (PROM) 9/37 (24%)
Premature delivery 12/37 (32.4%)
Intrauterine growth retardation (IUGR) 8/37 (22%)
Low birth weight (LBW) 7/37 (18.9%)
Number of babies admitted to NICUa 6/30 (20%)
Number of neonatal deaths 4/30 (13%)
Number of fetal losses 9/37 (24%)
Antenatal SLE ﬂare up during pregnancy 21/32 (65%)
Pre-eclampsia 8/37 (19.4%)
Postpartum ﬂare 8/37 (35.5%)
a NICU: neonatal intensive care unit.
136 A. Mokbel et al.reasons for cesarean section were obstetric complications such
as oligohydramnios, severe pregnancy induced hypertension,
premature rupture of membranes and fetal distress. One pa-
tient had history of elevated pulmonary artery pressure
(70 mmHg). She was treated (prior to pregnancy) with ste-
roids, warfarin, sildenaﬁl citrate and oral cyclophosphamide.
The pulmonary artery pressure decreased to 40 mmHg. She
announced unplanned pregnancy. The patient was maintained
on 10 mg steroids and low molecular weight heparin with fre-
quent follow up of the pulmonary artery pressure which main-
tained at 35–40 mmHg during pregnancy with uneventful
course during pregnancy and labor at term.Table 5 Predictors of adverse fetal and maternal outcomes.
Predictors Univariate ana
Fetal loss
Planned pregnancy 0.05
Activity at beginning of pregnancy 0.02
Prematurity
Lupus ﬂare 0.02
Age at pregnancy 0.04
Systemic lupus ﬂare up during pregnancy
Lupus anticoagulant antibodies (LAC) 0.02
Preeclampsia
Renal disease 0.04
a Chi-square test.
Table 4 Types and distribution of antenatal SLE ﬂare.
Type of SLE ﬂare SLE ﬂare up during pregnancy
n (%)
Distribution
1st trimester
Renal 7 (18.9) 3
Anemia 5 (13.5) 1
Arthritis 3 (8.1) 1
Neurological 2 (5.4) 0
Hepatitis 2 (5.4) 0
Pneumonitis 2 (5.4) 1
Serositis 0 03.4. Predictors of adverse fetal and maternal outcomes
Planned pregnancy was a predictor of good fetal outcome
(P= 0.048). In addition, activity at onset of pregnancy was
a predictor of fetal loss (P= 0.016) at univariate analysis.
However, they were no signiﬁcant predictors of fetal loss at
binary logistic regression analysis. On the other hand, ﬂare
during pregnancy, renal or neurological involvement, anti
Ro or La, antiphospholipid antibodies did not correlate with
the fetal loss. Prematurity was associated with ﬂare during
pregnancy (P= 0.02). Also, the younger age of pregnancy
was signiﬁcantly associated with prematurity (P= 0.04).
But, again the binary logistic regression analysis showed no
correlation. Lupus anticoagulant presence was a signiﬁcant
predictor of SLE antenatal ﬂare up at both univariate
(p= 0.02) and binary logistic regression analyses (p= 0.03).
Renal lupus disease was found to be a predictor of pre-eclamp-
sia occurrence (P= 0.04). Table 5
4. Discussion
SLE can be detrimental to pregnancy and may cause adverse
pregnancy outcomes. Conversely, pregnancy can cause ﬂares
of lupus disease activity [11].
Although the outcome of pregnancy in patients with SLE
has improved considerably in recent years, the frequency of fe-
tal loss remains higher than that in matched pregnant controls
[5].lysisa (P) Binary logistic regression analysis
NS
NS
NS
NS
OR: 14.3, 95% CI (1.27–42.9), P= 0.03
NS
of antenatal SLE ﬂare up Postpartum SLE ﬂare up
(n= 8)
2nd trimester 3rd trimester
2 2 4
3 1 0
1 1 1
2 0 0
2 0 0
1 0 0
0 0 3
Could women with systemic lupus erythematosus (SLE) have successful pregnancy 137There is paucity of data in regard to lupus pregnancy in
developing countries. In our study, the live birth rate was
81% of lupus pregnancies and this is in accordance with
other studies that showed a live birth rate of 72.9–89.7%
[12–17]. This live birth rate is somewhat high when com-
pared to other series which reported a live birth rate of
45% and 50% [18,19]. The high live birth rate in our study
could be explained by high percentage of planned preg-
nancy, low number of patients with active disease at preg-
nancy onset (only 5 cases), proper anticoagulation and the
use of hydroxychloroquine by all cases. In univariate analy-
sis, unplanned pregnancy was a predictor of fetal loss. Le
Thi Huong et al. emphasized the role of planned pregnancy
in good fetal outcome as they found that the fetal survival
rate in planned pregnancies was 92% which is close to that
observed in the French population [2].
Activity at onset of pregnancy was also found to be a pre-
dictor of fetal loss in univariate analysis. This is in accordance
with Clowse et al. who found the risk of fetal loss is increased
in women with active lupus [20]. Regression analysis failed to
ﬁnd predictors of fetal loss.
In contrary to others, our study failed to ﬁnd other predic-
tors of fetal loss like hypocomplementemia, elevated levels of
anti-DNA antibodies, aPL, or thrombocytopenia [21,22].
Prematurity was reported in 13 (36.1%). Reported inci-
dences of preterm delivery in SLE pregnancies have ranged be-
tween 17% and 49% [23–26].
Clark and colleagues report a modest, albeit insigniﬁcant,
trend toward a decrease in preterm deliveries from 1980 to
2000 (37.5–32%, respectively) [27]. In accordance to them,
our study showed that early delivery was due to spontaneous,
e.g., premature rupture of membranes and/or preterm labor,
or the result of planned induction because of deteriorating
maternal or fetal well-being. Flare during pregnancy was asso-
ciated with prematurity. The effect of maternal disease activity
as it relates to prematurity was also addressed in the Hopkins
study [20]. Active lupus nephritis was correlated to prematurity
in systematic review and meta-analysis of pregnancy outcomes
in patients with SLE and lupus nephritis [28]. Le Thi Huong
and his colleagues found that the younger maternal age was
the only correlate with prematurity [29]. This agrees with our
ﬁnding of statistically younger age of pregnancy in mothers
of preterm babies.
In our study, the growth retardation rate was 22.5%.
This ﬁgure is consistent with those reported from developed
countries [17,18,20,30]. Other studies reported different inci-
dences of growth retardation 10% [31] and 31% [13]. A
nationwide population-based study showed an increased
incidence of growth retardation in SLE patients (28.5% vs.
17.5%) compared to those without [32]. The greatest risk
for SLE mothers during pregnancy is the occurrence of a
disease relapse. Some studies showed that SLE ﬂares up
more during pregnancy [3,20,33] whereas others showed no
differences [34–36]. In our study, 21 of 36 pregnancies were
associated with a disease ﬂare during pregnancy and 8 ﬂare
during postpartum period. The reported rates of maternal
lupus ﬂares ranged from 5.7% to 35.3% among the develop-
ing countries [14]. The only exception was from a cohort
from Brazil [17], which reported maternal ﬂare rate of
85.3%. While there is uncertainty about the effect of preg-
nancy on the course of SLE, there is some evidence thatthe hormonal manipulation required for in vitro fertilization,
may result in increased disease activity [37,38].
Most ﬂares occurred in the second trimester (50% of the 18
ﬂares during pregnancy). Incidence of ﬂares is reported to be
higher in the second trimester and lower in the third [39–42].
In SLE pregnant women, estrogen, progesterone, testosterone
and DHEAS serum levels do not show a peak in the third tri-
mester as expected in healthy women [39,43]; a ﬁnding that
could be related to timing of ﬂares.
SLE ﬂare during pregnancy and post partum period are
usually mild to moderate, with a predominance of cutaneous
and articular manifestations [39,40,44–46]. In the current
study, nephritis was the most frequent manifestation of ﬂare
followed by hemolytic anemia, arthritis, CNS, pneumonitis,
and hepatitis. During postpartum period, serositis was the
most frequent followed by nephritis and arthritis. Nephritis
being the most common form of ﬂare in our study may
be due to the sample type as nephritis was present in a high
percentage 16/37 (43.2%) of the patients. They were follow-
ing with us regularly because of the fear of unfavorable
outcome.
The risk factors for increased lupus activity in pregnancy
were identiﬁed as active lupus 6 months before conception,
multiple ﬂares in the years before conception and discontinua-
tion of hydroxychloroquine [22,30]. However, we did not ﬁnd
any correlates to ﬂare among our patients.
Preeclampsia was diagnosed in 19.4% of our patients.
Preeclampsia occurred in 3–26.1% of patients in developing
countries [16]. Preeclampsia is a frequent complication of
pregnancy in SLE, occurring in approximately 13 percent
of patients [47]. Using univariate analysis renal disease is
found to be a predictor for preeclampsia which is in accor-
dance to Nossent et al., who reported higher rates of pre-
eclampsia in SLE patients with renal disease [48]. Other
studies recorded antiphospholipid antibodies (aPL), diabetes
mellitus, and prior episode of preeclampsia to be predictors
of preeclampsia [49].
Major limitation of this study relates to the sample size.
Multiple regression analysis failed to ﬁnd predictors for fetal
and maternal outcomes. Surprisingly lupus anticoagulant
was found to be a predictor for lupus ﬂare in multiple
regression analysis. In our study, twenty patients had anti-
phospholipid syndrome. Nine of them had positive lupus
anticoagulant. This large number compared to the studied
population may explain the signiﬁcant correlation found.
In conclusion, twenty years ago, medical textbooks said
that women with lupus should not get pregnant because of
the risks to both the mother and unborn child. Today, most
women with lupus can safely become pregnant. With proper
medical care, you can decrease the risks associated with
pregnancy and deliver a normal, healthy baby. The fetal
outcome is relatively good among the studied patients. No
maternal mortalities were recorded. We reported a high per-
centage of maternal ﬂare and most ﬂares were renal and oc-
curred during the second trimester. A larger study should be
conducted to deﬁne the predictors of maternal and fetal out-
comes in Egyptian pregnant lupus patients.
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